DOR BioPharma Announces Collaboration With Numoda Corporation for the Execution of Confirmatory,...

Posted on: Monday, 30 June 2008, 09:03 CDT DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a collaboration with Numoda Corporation (Numoda), experts in rapid information turnaround, for the execution of its upcoming confirmatory, Phase 3 clinical trial of orBec(R) for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD). Collaborating with Numoda will allow DOR to take full advantage of a comprehensive scope of services including using their robust industry benchmarking capabilities to develop an accurate operational and financial plan including the use... [read full story]